PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 5, 2019Journal of Clinical Oncology92 citationsOpen Access

Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer

DDDaniel C. DanilaRSRussell Z. SzmulewitzUVUlka N. Vaishampayan

Key Points

Key points are not available for this paper at this time.

Abstract

DSTP3086S has acceptable safety at the recommended phase II dose level of 2.4 mg/kg once every 3 weeks. Antitumor activity at doses between 2.25 and 2.8 mg/kg once every 3 weeks supports the potential benefit of treating STEAP1-expressing metastatic castration-resistant prostate cancer with an STEAP1-targeting antibody-drug conjugate.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Danila et al. (2019) studied this question.

synapsesocial.com/papers/69d776f55f9a1dad5349047ahttps://doi.org/10.1200/jco.19.00646
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.1990 · 287 citations
  2. 2New Guidelines to Evaluate the Response to Treatment in Solid Tumors2000 · 15,763 citations
  3. 3STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors1999 · 358 citations
  4. 4Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer2008 · 2,201 citations
  5. 5Development of potent monoclonal antibody auristatin conjugates for cancer therapy2003 · 1,203 citations